Search

From @scientiff via Twitter: Hey #scitwitter! I’m troubleshooting some #phage DNA extraction woes with our undergrads. We use phenol-chloroform-isoamyl and phase-lock gels for the process but we’re still getting high 260/230 after elution.

The first patient in Armata Pharmaceuticals’ newest trial has been treated. This is part of the Phase 2a portion of their diSArm study, which evaluates the potential treatment of S. aureus bacteremia.

Jason Wilson (University of Sheffield) and colleagues published a new preprint on the molecular mechanism of phage tail contraction, shedding light on the structure of an S-layer-penetrating phage.

In a new Current Opinion in Microbiology piece, Jochen Klumpp, Matthew Dunne, and Martin Loessner explore the potential of phage receptor-binding proteins for diagnostic and therapeutic applications.

Juergen Eckhardt, writing for Forbes magazine, recently wrote an article on phage therapy.

Min Wang (Ocean University of China) and colleagues have identified a new Halomonas phage in the Mariana Trench. This is the deepest known phage isolation.

Phage Bites is back! The Bacteriophage Biology & Therapeutics (BBT) SIG is hosting their second symposium Sept 26 featuring brief presentations from postgraduate students on phage-related topics, followed by an expert panel discussion on "S

The 4th International Conference on Bacteriophage Research and Antimicrobial Resistance is hosting ”Phages for Life”, a hybrid conference from Sept 28-30 in Chennai, India and online, with the theme of “Harnessing bacteriophages for human w

Phage Futures 2023, a free, one-day online conference which aims to bring together phage researchers and industry professionals to explore phage commercialization, is being hosted online October 25th by Kisaco Research. Read the full Agenda

Australia’s The Project showcases new Phage Australia work on a new children's CF clinical trial using phages.

Parallel Health, a new US phage skincare company, has announced $2.3M in funding and launched a custom phage therapy skin serum that targets bacteria causing skin conditions, offering personalized treatments based on individual skin microbi

Contrafect, a company developing ‘direct lytic agents’ (which include lysins and amurin peptides), has submitted an IND application for preliminary approval of a new IV antibacterial agent for treatment of hospital-acquired and ventilator-a

Benjamin Adler and colleagues have developed a broad-spectrum phage functional genomics platform using programmable RNA-binding protein dRfxCas13d, uncovering hidden infection strategies and predicting over 90 essential genes in phage genom

Jingxian Yang and colleagues have discovered that agr (quorum sensing) induction reduces expression of tarM (which encodes a glycosyltransferase responsible for modification of the major S. aureus phage receptor). This allows lytic phage St

Phables, a new computational method developed by Vijini Mallawaarachchi and colleagues, resolves phage genomes from fragmented viral metagenome assemblies, enabling the recovery of over 49% more high-quality phage genomes compared to existi

Researchers led from the Ocean University of China characterised Halomonas phage vB_HmeY_H4907, isolated from surface sediment of the Mariana Trench at a depth of 8,900 m. The authors describe it as the deepest isolated siphovirus from the

University of California, Berkeley researchers report the first observation of heat-induced electrical potential generation on a virus, studying the pyroelectric properties of the M13 phage. Modifying the pVIII coat protein with different n

Did you know that VoM is heading down under? The Viruses of Microbes (VoM) Conference will take place in Cairns, Queensland, Australia, July 15-19th, 2024. Registration is open now!

Katelyn McNair, the creator of Phanotate, has introduced a new tool called Genotate, designed to identify and predict coding genes in phage genomes. Now in final stages of development, it’s built to take your phage genome annotation and an

Intralytix has announced the launch of a Phase 1/2a clinical trial of its VRELysin™ phage preparation to assess safety and efficacy in healthy and VRE-colonized subjects at UPMC in Pittsburgh, Pennsylvania.